Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242316773 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Perla Chami und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The liver tumor immune microenvironment has been thought to possess a critical role in the development and progression of hepatocellular carcinoma (HCC). Despite the approval of immune checkpoint inhibitors (ICIs), such as programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) inhibitors, for several types of cancers, including HCC, liver metastases have shown evidence of resistance or poor response to immunotherapies. Radiation therapy (RT) has displayed evidence of immunosuppressive effects through the upregulation of immune checkpoint molecules post-treatment. However, it was revealed that the limitations of ICIs can be overcome through the use of RT, as it can reshape the liver immune microenvironment. Moreover, ICIs are able to overcome the RT-induced inhibitory signals, effectively restoring anti-tumor activity. Owing to the synergetic effect believed to arise from the combination of ICIs with RT, several clinical trials are currently ongoing to assess the efficacy and safety of this treatment for patients with HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon.
- Faculty of Medicine, University of Balamand, Beirut 1100, Lebanon.
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA.
- Department of Surgery, Weill Medical College, Cornell University, New York, NY 10021, USA.
- Department of Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA.
- New York Proton Center, New York, NY 10035, USA.
ORCID-Profile: Perla Chami, Youssef Diab, James J Harding
Förderung
- NCI NIH HHS
Zitieren
APA
Chami, P., Diab, Y., Khalil, D. N., Azhari, H., Jarnagin, W. R., Abou-Alfa, G. K., Harding, J. J., Hajj, J., Ma, J., El Homsi, M., Reyngold, M., Crane, C., & Hajj, C. (2023). Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316773
Vancouver
Chami P, Diab Y, Khalil DN, Azhari H, Jarnagin WR, Abou-Alfa GK, et al. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316773
BibTeX
@article{Chami2023,
author = {Chami, Perla and Diab, Youssef and Khalil, Danny N and Azhari, Hassan and Jarnagin, William R and Abou-Alfa, Ghassan K and Harding, James J and Hajj, Joseph and Ma, Jennifer and El Homsi, Maria and Reyngold, Marsha and Crane, Christopher and Hajj, Carla},
title = {Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242316773}
}
EUVIMED